Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study

T. Waddell1*, K. Fife2, R. Griffiths3, A. Sharma4, P. Dhokia5, L. Groves6, M. Hurst5,6, C. Tsang6, D. Sugrue6, S. McKenna6, J. Houghton6 and R. Carroll5

Abstract
Background: The CheckMate 025 trial established nivolumab monotherapy as one of the standards of care in previously treated advanced or metastatic renal cell carcinoma (aRCC). However, supporting real-world data is lacking. This study investigated characteristics, treatment sequences and clinical outcomes of patients who received nivolumab monotherapy for previously treated aRCC in the UK.

Methods: This was a retrospective cohort study of aRCC patients treated with nivolumab at second line or later (2L +) at 4 UK oncology centres. Eligible patients commenced nivolumab (index date) between 01 March 2016 and 30 June 2018 (index period). Study data were extracted from medical records using an electronic case report form. Data cut-off (end of follow-up) was 31 May 2019.

Results: In total, 151 patients were included with median follow-up of 15.2 months. Mean age was 66.9 years, male preponderance (72.2%), and mostly Eastern Cooperative Oncology Group performance status grade 0–1 (71.5%). Amongst 112 patients with a known International Metastatic RCC Database Consortium score, distribution between favourable, intermediate, and poor risk categories was 20.5%, 53.6%, and 25.9% respectively.

The majority of patients (n = 109; 72.2%) received nivolumab at 2L, and these patients had a median overall survival (OS) of 23.0 months [95% confidence interval: 17.2, not reached]. All patients who received nivolumab at 2L had received TKIs at 1L. Amongst the 42 patients (27.8%) who received nivolumab in third line or later (3L +) the median OS was 12.4 months [95% CI: 8.8, 23.2]. The most common reasons for nivolumab discontinuation were disease progression (2L: 61.2%; 3L: 68.8%) and adverse events (2L: 34.7%; 3L: 28.1%).

Conclusion: This study provides real-world evidence on the characteristics, treatment sequences, and outcomes of aRCC patients who received 2L+ nivolumab monotherapy in the UK. Nivolumab-specific survival outcomes were similar to those achieved in the CheckMate 025 trial.

*Correspondence: tom.waddell@nhs.net; angelawright10@nhs.net

1 Gastro-Oesophageal and Renal Unit, The Christie NHS Foundation Trust, Manchester, UK

Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Kidney cancer poses a significant burden to public health and clinical practice, with Europe having some of the highest incidence rates in the world [1]. In the United Kingdom (UK), kidney cancer is the 7th most common cancer, accounting for 4% of all new cancer cases and with approximately 13,100 new diagnoses per year, based on published data from 2015–2017 [2]. The incidence of kidney cancer is projected to rise by 26% between 2014 to 2035, to 32 cases per 100,000 people [2]. The most common type of kidney cancer is renal cell carcinoma, which accounts for approximately 80% of cases [3]. When diagnosed at its earliest stage (stage I), 96% of patients survive for a year or more, whereas in advanced or metastatic renal cell carcinoma (aRCC) only 39% of patients survive for a year or more [4]. In the UK, between 25 and 31% of patients diagnosed with kidney cancer have aRCC at diagnosis [5–8]. Additionally, amongst patients who have curative resection for early stage RCC (stages I and II), approximately half go on to develop advanced and/or metastatic disease at a later time point [6].

The treatment options for aRCC have expanded over the last decade with the introduction of targeted agents including tyrosine kinase inhibitors (TKIs) and inhibitors of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) [9, 10]. More recently, the introduction of immune checkpoint inhibitors (ICIs) has significantly improved patient outcomes and has provided clinicians with greater choice and flexibility when selecting anti-cancer therapies [11]. Nivolumab is an ICI that blocks the interaction between programmed cell death protein-1 (PD-1) expressed on T cells and its ligands programmed cell death protein ligand-1 (PD-L1) and PD-L2, expressed on antigen-presenting cells and cancer cells [12, 13]. The efficacy and safety of nivolumab has been demonstrated in CheckMate 025 (NCT0166874), a phase III randomised controlled trial (RCT) of nivolumab monotherapy in patients with refractory aRCC [14]. Patients in the nivolumab monotherapy arm had significantly longer median overall survival (OS) and more favourable safety outcomes compared with patients who received the comparator, everolimus [15, 16]. In the UK, nivolumab was approved for previously treated advanced renal cell carcinoma by the National Institute for Health and Care Excellence in 2016 [17].

Due to the high selectivity of clinical trial populations and controlled study conditions, trial outcomes may not represent the wider aRCC population in routine clinical practice [18]. Supplementary real-world evidence (RWE) may support and complement the evidence generated through clinical trials by providing information on the characteristics of patients, treatment sequences, and outcomes that are more reflective of real-world clinical practice [18]. Therefore, the aim of this study was to generate RWE on the treatment sequences and clinical outcomes of patients with previously treated aRCC who received nivolumab monotherapy in the UK.

Methods

Study design

This was a multi-centre, retrospective cohort study of adult patients with previously treated aRCC who received nivolumab monotherapy in the UK. Data were collected from medical records at four specialist National Health Service (NHS) cancer treatment centres in England.

The study was approved by the Health Research Authority (Reference: 257,930). A minor amendment was submitted to the HRA and approved on 23 June 2020. Ethical approval was received from the Yorkshire & The Humber – Bradford Leeds Research Ethics Committee (Reference: 19/YH/0185).

Study sample

Eligible patients were identified through screening of medical records at participating secondary care study centres. Patients were included in the study if they met all study eligibility criteria: ≥ 18 years at RCC diagnosis; had a primary diagnosis of aRCC; and received nivolumab monotherapy for aRCC as under licenced uses (second or subsequent lines of therapy[LOTs]) during the index period (01 March 2016 to 30 June 2018). Patients were excluded if they were diagnosed with malignant tumours other than RCC, had incomplete treatment information, had inadequate treatment follow-up (i.e., < 6 months post index date [date of nivolumab monotherapy initiation for aRCC]), received nivolumab at first line (1L), or received nivolumab within a clinical trial.

Data collection

Data were sourced from the medical records of a sample of eligible patients at each study centre from the date of initiation of the first treatment for aRCC to the earliest of the following: most recent visit, death, or end of follow-up (EOFU) on 31 May 2019. The study window was chosen to provide a contemporaneous dataset of patients with up to three years of follow up data. Clinical data were extracted from medical records at each study centre.
and collected for this study using a bespoke electronic case report form (eCRF) in Microsoft Excel. The study investigators (SIs) at each study centre were responsible for patient identification, eligibility assessment, and completion of the eCRF. Study data within the eCRF were pseudo-anonymised by SIs at each centre prior to delivery to the contract research organisation for analysis. Data collection was entirely retrospective and did not involve any direct patient contact.

**Study outcomes**

Overall survival (OS) was the primary outcome measure and was defined as the time between index date and either date of death or most current medical record at EOFU. This was assessed for both the overall study cohort and stratified by the treatment line in which nivolumab was initiated.

Time on therapy and discontinuation were secondary objectives, where time on LOT was defined from initiation of the treatment to the earliest of the following: date of LOT discontinuation, death, lost to follow-up (LTFU), or the most current medical record at EOFU. Time on LOT was calculated for the overall study cohort, and for subgroups of patients receiving nivolumab at different lines of therapy.

**Treatment switching definitions**

In line with previous studies [19] and based on advice from the SIs, treatment switches due to intolerability in this study were limited to 1L treatment only, and applied to switches to/from sunitinib, pazopanib, and tivozanib only as these TKIs share similar efficacy and safety profiles [20]. The implementation of these treatment switching rules ensured the consistent capturing of treatment sequences across all study centres.

Of the original study cohort, six (4.0%) patients were recorded to have received interleukin-2 (IL-2) therapy at 1L, which was not counted as a LOT for the treatment sequencing and treatment pathway analyses.

**Statistical analysis**

This study did not test any hypotheses and therefore a formal sample size calculation was not undertaken to determine statistical power. Baseline patient demographic and clinical characteristics were analysed descriptively, where baseline was defined as the index date. Categorical data were reported using frequencies and percentages, with 95% confidence intervals (CIs). Continuous data were reported using mean and standard deviation (SD). Differences between subgroups were assessed using t-tests and chi-squared tests. OS and time on LOT were calculated using Kaplan–Meier methods. Log-rank and Wilcoxon signed-ranked tests were used to assess for differences between subgroups. All analyses were carried out using R version 3.61.

**Results**

**Patient characteristics**

In total, 151 patients (mean age 66.9 years [SD 10.0], male 72.2% at index), met eligibility criteria, were sampled randomly to be included in the study, and were included in analyses. The median (interquartile range [IQR]) time from aRCC diagnosis to nivolumab initiation was 2.0 years (IQR 0.9–3.6) (Table 1), and median follow-up from index was 15.2 months (IQR 8.7–22.4). Where prognostic risk (International Metastatic RCC Database Consortium [IMDC] classification) was recorded (n = 112), 53.5% (n = 60) patients were classified as intermediate risk. The majority of patients had an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 (n = 49; 32.5%) or 1 (n = 59; 39.1%) at index. The majority of the patient cohort had clear cell histology (n = 131; 86.8%) and prior nephrectomy (n = 110; 72.8%). The most frequently reported sites of metastasis were lung (n = 116; 76.8%), lymph nodes (n = 65; 43.0%), bone (n = 53; 35.1%), and liver (n = 43; 28.5%).

Patient demographics including age, sex distribution, ECOG PS, prior nephrectomy status, and sites of metastases were similar across nivolumab-specific treatment lines (Table 1).

**Transition rates**

In total, 72.2% (n = 109) of the cohort received nivolumab at second line (2L) and 27.8% (n = 42) received nivolumab at third line or later (3L+). Among the 109 patients who received nivolumab at 2L, 52 (47.1%) received further treatment at 3L in the index and follow-up periods; of these, 14 (26.9%) went on to receive fourth line (4L), and of these, 1 (7.1%) went on to receive fifth line (5L). Of the 36 patients that received nivolumab at 3L, 12 (33.3%) received further treatment at 4L and of these, 3 (25.0%) patients received 5L within the follow-up period. Two (40.0%) of the five patients who received nivolumab at 4L transitioned to 5L.

**Time on LOT**

Median time on LOT for any treatment decreased with increasing therapy line, ranging from 7.8 months (95% CI: 6.9, 9.9) in 1L to 4.6 months (95% CI: 3.0, NR) in 5L. For nivolumab-specific LOTs, median time on nivolumab monotherapy was 4.1 (95% CI: 3.1, 6.4), 4.5 (95% CI: 3.1, 9.7), 3.5 (95% CI: 2.1, NR), and 4.3 months (95% CI: NA, NA) for 2L, 3L, 4L, and 5L, respectively (Wilcoxon [W]: 0.41, Log-Rank [LR]: 0.25) (Fig. 1). No patients who received nivolumab at 4L and 5L remained on treatment.
### Table 1  Patient demographics and clinical characteristics at index (date of nivolumab initiation)

| Variable                                      | LOT Nivolumab was received | p-value<sup>b</sup> |
|-----------------------------------------------|-----------------------------|---------------------|
|                                                | All patients at index date<sup>a</sup> (n = 151) | 2L (n = 109) | 3L+ (n = 42) |
| **n, % (95% CI) unless otherwise stated**     |                             |                   |              |
| **Age (years)**                               |                             |                   |              |
| Mean (SD)                                     | 66.9 (10.0)                 | 67.2 (10.2)        | 66.2 (9.4)   | 0.58         |
| Median (IQR)                                  | 66.9 (60.4,74.3)            | 67.4 (59.8,75.3)   | 66.2 (60.9,70.9) |             |
| **Sex**                                       |                             |                   |              |
| Female                                        | 42, 27.8% (21.3,35.4)       | 28, 25.7% (18.4,34.6) | 14, 33.3% (21.0,48.4) | 0.46         |
| Male                                          | 109, 72.2% (64.6,78.7)      | 81, 74.3% (65.4,81.6) | 28, 66.7% (51.6,79.0) |              |
| **Time from aRCC diagnosis to index date<sup>c</sup> (years)** |                         |                   |              |
| Mean (SD)                                     | 2.6 (2.5)                   | 2.0 (1.8)          | 4.2 (3.1)   | <0.01<sup>a</sup> |
| Median (IQR)                                  | 2.0 (0.9,3.6)               | 1.4 (0.7,2.9)      | 3.4 (2.0,5.9) |             |
| **ECOG PS at index<sup>a</sup>**              |                             |                   |              |
| 0 (fully active)                              | 49, 32.5% (25.5,40.3)       | 38, 34.9% (26.6,44.2) | 11, 26.2% (15.3,41.1) | 0.66         |
| 1 (restrictive)                               | 59, 39.1% (31.7,47.0)       | 42, 38.5% (29.9,47.9) | 17, 40.5% (27.0,55.5) |             |
| 2 (off-work)                                  | 19, 12.6% (8.2,18.8)        | 13, 11.9% (7.1,19.3) | 6, 14.3% (6.7,27.8) |             |
| 3 (limited)                                   | 3, 2.0% (0.7,5.7)           | 3, 2.8% (0.9,7.8)   | 0, 0.0% (0.0,8.4) |             |
| 4 (bedbound)                                  | 0, 0.0% (0.0,2.5)           | 0, 0.0% (0.0,3.4)   | 0, 0.0% (0.0,8.4) |             |
| Not available§                                | 21, 13.9%                   | 13, 12%            | 8, 19.1%    |             |
| **IMDC classification (Heng points) at index<sup>a</sup>** |                             |                   |              |
| Favourable (0)                                | 23, 15.2% (10.4,21.8)       | 17, 15.6% (10.0,23.6) | 6, 14.3% (6.7,27.8) | 0.02<sup>a</sup> |
| Intermediate (1–2)                            | 60, 39.7% (32.3,47.7)       | 34, 31.2% (23.3,40.4) | 26, 61.9% (46.8,75.0) |             |
| Poor (3)                                      | 29, 19.2% (13.7,26.2)       | 25, 22.9% (16.0,31.7) | 4, 9.5% (3.8,22.1) |             |
| Unknown                                       | 39, 25.8% (19.5,33.4)       | 33, 30.3% (22.4,39.5) | 6, 14.3% (6.7,27.8) |             |
| **Histological subtype**                     |                             |                   |              |
| Clear Cell                                    | 131, 86.8% (80.4,91.3)      | 93, 85.3% (77.5,90.8) | 38, 90.5% (77.9,96.2) | 0.39         |
| Non-clear: papillary                         | 7, 4.6% (2.3,9.3)           | 6, 5.5% (2.5,11.5)  | 1, 2.4% (0.1,12.3) |             |
| Non-clear: collecting duct                    | 0, 0.0% (0.0,2.5)           | 0, 0.0% (0.0,3.4)   | 0, 0.0% (0.0,8.4) |             |
| Non-clear: chromophobe                       | 4, 2.6% (1.0,6.6)           | 4, 3.7% (1.4,9.1)   | 0, 0.0% (0.0,8.4) |             |
| Non-clear: sarcomatoid                       | 2, 1.3% (0.4,4.7)           | 2, 1.8% (0.5,6.4)   | 0, 0.0% (0.0,8.4) |             |
| Not available§                                | 7, 4.6%                     | 4, 3.6%            | 3, 7.1%     |             |
| **Prior nephrectomy**                         |                             |                   |              |
| Yes                                           | 110, 72.8% (65.3,79.3)      | 76, 69.7% (60.5,77.6) | 34, 81.0% (66.7,90.0) | 0.24         |
| **Site of metastasis**                        |                             |                   |              |
| Bone                                          | 53, 35.1% (27.9,43.0)       | 37, 33.9% (25.7,43.2) | 16, 38.1% (25.0,53.2) | 0.77         |
| Brain                                         | 19, 12.6% (8.2,18.8)        | 15, 13.8% (8.5,21.5) | 4, 9.5% (3.8,22.1) | 0.67         |
| Soft tissue                                   | 12, 7.9% (4.6,13.4)         | 9, 8.3% (4.4,15.0)   | 3, 7.1% (2.5,19.0) | 1.00         |
| Lung                                          | 116, 76.8% (69.5,82.8)      | 85, 78.0% (69.3,84.7) | 31, 73.8% (58.9,84.7) | 0.74         |
| Lymph nodes                                   | 65, 43.0% (35.4,51.0)       | 47, 43.1% (34.2,52.5) | 18, 42.9% (29.1,57.8) | 1.00         |
| Liver                                         | 43, 28.5% (21.9,36.1)       | 27, 24.8% (17.6,33.6) | 16, 38.1% (25.0,53.2) | 0.15         |
| Other                                         | 33, 21.9% (16.0,29.1)       | 20, 18.3% (12.2,26.6) | 13, 31.0% (19.1,46.0) | 0.14         |
| None                                          | 3, 2.0% (0.7,5.7)           | 3, 2.8% (0.9,7.8)   | 0, 0.0% (0.0,8.4) | 0.66         |

<sup>a</sup> Index date defined as date of nivolumab initiation; <sup>b</sup>p-values for tests of differences between treatment subgroups (2L and 3L+); <sup>c</sup>Due to the re-synthesising of treatment pathways as a result of adjusting for intolerability, some data points, specifically ECOG PS were not collected and therefore have been labelled as information unavailable to differentiate from unknown data points.

aRCC Advanced renal cell carcinoma, CI Confidence interval, ECOG PS Eastern cooperative oncology group performance status, IMDC International metastatic renal cell carcinoma database consortium, LOT Line of therapy, N Total population, n Sampled population, SD Standard deviation.
past 6 months. Percentage of patients remaining on treatment at 12, 24, and 36 months were 24.7%, 4.9%, and NA for 2L nivolumab and 25.0%, 15.0%, and 5.0% for 3L nivolumab, respectively.

Treatment sequences
Pazopanib (n = 81; 53.6%) and sunitinib (n = 47; 31.1%) were most frequently received at 1L without switching (Fig. 2). First-line TKI switching occurred in 17 (11.3%) patients (pazopanib➔sunitinib, n = 8 [47.1%]; sunitinib➔pazopanib, n = 8 [47.1%]; and sunitinib➔pazopanib➔sunitinib, n = 1 [5.9%]). All patients who received nivolumab at 2L (n = 109) had received TKIs at 1L, including pazopanib (n = 63; 57.8%), and sunitinib (n = 33; 30.3%). Eleven (10.1%) received both sunitinib and pazopanib at 1L. After receiving nivolumab at 2L, 52 patients (47.7%) went on to receive 3L treatment in the follow-up period, including cabozantinib (n = 36; 69.2%), axitinib (n = 11; 21.2%), everolimus (n = 1; 1.9%), lenvatinib and everolimus (n = 1; 1.9%), sofarenib (n = 1; 1.9%), or pazopanib (n = 1; 1.9%). One patient (1.9%) who received 2L nivolumab also received repeat treatment of nivolumab at 3L (Fig. 2).

At 3L, 36 (38.3%) patients received nivolumab (Fig. 2). Most of these patients had prior treatment with 1L
sunitinib or pazopanib and then followed by 2L axitinib ($n = 22, 61.1\%$). Five patients received nivolumab at 4L, where prior 3L treatment included cabozantinib ($n = 2$), sunitinib ($n = 2$), and everolimus ($n = 1$).

**Survival outcomes**
Overall, median OS from nivolumab initiation was 19.2 months [95% CI, 16.9–27.0]. Median OS was 23.0 months (95% CI: 17.2, not reached) from initiation of nivolumab monotherapy at 2L, and OS was 73.9% (95% CI: 66.0, 82.7), 46.2% (95% CI: 36.0, 59.3), and 33.6% (95% CI: 19.6, 57.5) at 12, 24, and 36 months, respectively (Fig. 3). In comparison, median OS was 12.4 months (95% CI: 8.8, 23.2) from initiation of nivolumab monotherapy at 3L+, and OS was 52.4% (95% CI: 39.3, 69.9), 24.7% (95% CI: 13.7, 44.7), and 18.6% (95% CI: 8.2, 42.1) at 12, 24, and 36 months, respectively. Similar maximum length of follow-up was observed for 2L and 3L+nivolumab patients (38.4 months and 38.6 months, respectively) (Fig. 3).

**Treatment discontinuation**
Of the 151 patients included in analyses, 136 (90.1%) patients discontinued nivolumab monotherapy by the conclusion of the follow-up period (Table 2). The most common reasons for nivolumab discontinuation were progressed disease (including discontinuation due to death) (2L: 61.2%; 3L+: 71.1%) or discontinuation due to adverse events (2L: 34.7%; 3L+: 23.7%).

**Discussion**
This study provides insights into the real-world treatment sequences and outcomes of previously treated aRCC patients in clinical practice in the UK who received nivolumab monotherapy. Findings show that nivolumab-specific survival outcomes observed in the real-world setting were comparable to those reported in the pivotal CheckMate 025 trial [15, 16].

The majority of the study cohort were male (72.2%), with a mean age of 66.9 years at index, and had clear cell histology (86.8%). A greater percentage of the study sample had clear cell histology than reported in the wider UK RCC population (86.8% compared with approximately 75%), which may be partially explained by reimbursement instructions requiring a clear cell component or papillary RCC [21], but the remaining patient and clinical characteristics of the study sample were comparable to the broader UK kidney cancer [2, 22] and RCC population [2, 22, 23]. Furthermore, patient characteristics observed in this study were broadly comparable to those reported in CheckMate 025 (median age, 62 years; 77% male) [14].

Treatment sequences observed in this real-world study were largely reflective of NICE recommendations and national treatment guidelines available over the study period [24]. As expected, based on national
Fig. 3  Overall survival for 2L or 3L + nivolumab

Table 2  Reasons for discontinuation of nivolumab

|            | 2L (n = 109) | 3L (n = 36) | 4L (n = 5) | 5L (n = 1) |
|------------|--------------|-------------|------------|------------|
| Number discontinued | 98           | 32          | 5          | 1          |
| Reason for discontinuation: n, % (95% CI) |
| AE         | 34, 34.7 (26.0, 44.5) | 9, 28.1 (15.6, 45.4) | 0.0 (0.043.4) | 0.0 (0.793) |
| Progressed diseasea | 60, 61.2 (51.3, 70.3) | 22, 68.8 (51.4, 82.0) | 4.800 (37.6,96.4) | 1.100.0 (20.7,1000) |
| Patient choice | 0.0 (0.03.8) | 1.3 (0.6,15.7) | 0.0 (0.043.4) | 0.0 (0.793) |
| Other (please state) | 2, 2.0 (0.6,7.1) | 0.0 (0.010.7) | 0.0 (0.043.4) | 0.0 (0.793) |
| Not recorded | 2, 2.0 (0.6,7.1) | 0.0 (0.010.7) | 1, 20.0 (3.6,62.4) | 0.0 (0.793) |

* Including discontinuation due to death
AE Adverse event, CI Confidence interval, nl n<sup>ith</sup>/r<sup>th</sup>/s<sup>th</sup> line of therapy, PD Progressed disease
clinical guidelines [25, 26], patients in this study typically received TKIs either before or after nivolumab monotherapy. For example, pazopanib (64.9%) and sunitinib (42.4%) were the most common 1L treatments. Over two-thirds (67.9%) of 2L nivolumab patients received pazopanib at 1L, either as the only treatment or in a sequence of 1L treatments. At the time of study, recommended 2L and 3L aRCC treatment options in England and Wales included axitinib, nivolumab, cabozantinib, everolimus, or dual therapy lenvatinib with everolimus [17, 27–30]. In our cohort, most patients (61.1%) who received nivolumab at 3L had previously received axitinib at 2L. Cabozantinib most frequently followed 2L and 3L nivolumab monotherapy. However, while NICE recommends everolimus as a 4L therapy option [29], few patients actually received this drug, which may reflect a general trend towards decreased use of single agent everolimus. Patients who reached 4L therapy in our cohort commonly received cabozantinib (50.0%). Among the study cohort, 4 patients across all LOTs received lenvatinib with everolimus; potentially because lenvatinib combined with everolimus is only recommended for those with ECOG PS performance scores of 0–1 and only following one prior VEGF-targeted therapy [24].

Of the 136 patients who discontinued nivolumab regardless of treatment line, 31.6% discontinued due to adverse events.

Median OS (95% CI) for 2L nivolumab patients in this study was 23.0 months (95% CI: 17.22, not reached) and was comparable with median OS reported in the CheckMate 025 trial (25.8 months [95% CI, 22.2–29.8]) [14] and those achieved in similar real-world retrospective studies conducted in Italy (22.5 months) [31], the Netherlands (18.7 months) [32], Croatia, Hungary, and Malta (18.0 months) [33].

There were some methodological limitations in this study. The analysis included results from 151 patients from four sites, which although geographically dispersed NHS England specialist cancer care centres, may not be representative of the wider aRCC population or treatment centres in England and the UK as a whole. Due to the retrospective use of medical record data, results may be affected by incomplete or inaccurate original data and inaccurate data entry using the eCRF, although efforts were made to reduce occurrence of the latter by applying in-built validation checks to the eCRF and the exclusion criterion citing incomplete treatment information. In addition, the representative nature of the study to real world practice may be limited as patients were only eligible for study inclusion if they received nivolumab monotherapy during the index period. As such, the study cohort was more likely to reach EOFU when receiving nivolumab monotherapy as opposed to prior, discontinued therapies.

The length of the index period also means that follow-up times varied considerably for the study cohort. This study contained an uneven distribution of patients from each of the centres. Although all centres were part of NHS England, disparity in patient numbers and local practices may affect treatment patterns and outcomes. Finally, it should also be noted that this study is descriptive in nature; and therefore, conclusions on the comparative efficacy between interventions cannot be made.

Despite these limitations, the strengths of this study included the choice of OS as a primary outcome measure, which is considered a robust measure of clinical benefit [34], and less affected by inconsistent recording which limits other intermediate endpoints such as disease progression. The implementation of treatment switching rules also ensured the consistent capturing of treatment sequences across all study centres. Future research could consider related endpoints such as progression-free survival, objective response rate and further investigation into the type and severity of adverse events to support understanding of the clinical effectiveness of treatments in the real-world setting.

Conclusions

The achievement of comparable OS outcomes for patients who received nivolumab monotherapy in clinical practice compared with clinical trials, as well as adherence to national clinical guidelines, should provide reassurance to clinicians prescribing nivolumab monotherapy, as well as patients receiving treatment. However, descriptions of outcomes based on specific treatment sequences are challenging due to bias that may be introduced through time-varying confounding in comparative analyses of real-world data. Although this study characterises previously treated aRCC patients who went on to receive nivolumab at later therapy lines, additional data from larger cohorts are needed to further assess effectiveness over time in the real-world setting for previously treated aRCC patients.

Abbreviations

1L: First line; 2L: Second line; 2L +: Second line and beyond; 3L: Third line; 3L +: Third line and beyond; 4L: Fourth line; 5L: Fifth line; aRCC: Advanced or metastatic renal cell carcinoma; CI: Confidence intervals; COVID-19: Coronavirus disease 2019; ECOG PS: Eastern Co-operative Oncology Group Performance Status; eCRF: Electronic case report form; EOFU: End of follow up; HRA: Health Research Authority; IC: Immune checkpoint inhibitor; IL-2: Interleukin-2; IMDC: International Metastatic renal cell carcinoma Database Consortium; IQR: Interquartile range; LOT: Line of therapy; LTFU: Lost to follow up; mTOR: Mammalian target of rapamycin; NHS: National Health Service; NICE: National Institute for Health and Care Excellence; OS: Overall survival; PD-L1: Programmed death ligand 1; RCT: Randomised controlled trial; RWE: Real-world evidence; SD: Standard deviation; SIs: Study investigators; TKI: Tyrosine kinase inhibitors; UK: United Kingdom; VEGF: Vascular endothelial growth factor.
Glossary

Advanced Cancer that is unlikely to be cured and generally have a poor prognosis
Electronic case report form Electronic data collection form used to input data by researchers at each centre
Metastatic A cancer that has spread from its site of origin to different parts of the body
Line of therapy Each course of treatment is defined as a line of therapy. A patient would move onto the next line of therapy if a treatment has not worked or has been stopped because of the occurrence of side effects or other concerns
Real-world evidence Evidence or data obtained from real-world practice, which is observational and obtained outside the context of controlled trials
Renal cell carcinoma The most common type of kidney cancer in adults that originates in the tubules of the kidney
Second-line These second treatment given to a patient once the initial (first-line) therapy has not worked or has been stopped because of the occurrence of side effects or other concerns
Time on line of therapy The time from initiation of a treatment to the end of treatment

Acknowledgements
Bryony McNamara at HEOR Ltd provided editorial support during the development of this manuscript.

Authors’ contributions
LG, CT, DS, PD, RC, and TW contributed to the study concept and design; TW, KF, RG and AS participated in the acquisition of the data; MH and JH performed the statistical analysis. All authors participated in the interpretation of data and the development, critical review, and editing of the manuscript. All authors have read and approved the final manuscript.

Funding
This work was funded by Bristol Myers Squibb Company Ltd and supported by Health Economics and Outcomes Research Ltd.

Availability of data and materials
The datasets generated and analysed during the current study are not publicly available. Some study data may be available from the study sponsor upon reasonable request. To request study data, please contact R. Carroll (Robert.Carroll@bms.com).

Declarations

Ethics approval and consent to participate

This retrospective chart review was conducted in accordance with the ethical standards of the Declaration of Helsinki. The study was approved by the Health Research Authority (Reference: 257930). Ethical approval was received from the Yorkshire & The Humber – Bradford Leeds Research Ethics Committee (Reference: 19/YH/0185). Data collection was entirely retrospective and involved no direct patient contact, therefore consent to participate was not required. The study and its methodology were reviewed and approved by the HRA and Yorkshire & The Humber – Bradford Leeds Research Ethics Committee which includes the requirement, or not, for informed consent. Therefore, informed consent was waived by Yorkshire & The Humber – Bradford Leeds Research Ethics Committee.

Consent for publication

Not applicable.

Competing interests

PD, MH and RC are employees of Bristol Myers Squibb Company Ltd. MH was employed at Health Economics and Outcomes Research Ltd at the time of study. LG, CT, DS, SM and JH are employees of Health Economics and Outcomes Research Ltd, Cardiff, UK, who received fees from Bristol Myers Squibb in relation to this study. TW reports: research funding, travel expenses, advisory boards and honoraria from BMS; research funding, advisory boards and honoraria from Pfizer; honoraria and travel expenses from EUSA; research funding, travel expenses, advisory boards and honoraria from Ipsen; advisory board for Eisai; and a research grant from Merck MSD. KF has received advisory, consultancy or speaker fees from EISAI, Ipsen, Roche, Novartis, Merck, Pfizer, Eusa, BMS, and Sanofi and conference support from Novartis, Ipsen and EUSA and Institutional research funding from Roche, Merck, Exelixis. AS has received advisory, consultancy or speaker fees from EISAI, Ipsen, Roche, Merck, Pfizer, Eusa, BMS, MSD and conference support from—Ipse, EUSA, BMS and MSD. For RG, no potential conflicts of interest were disclosed.

Author details

1Gastro-Oesophageal and Renal Unit, The Christie NHS Foundation Trust, Manchester, UK. 2Cambridge University NHS Foundation Trust, Cambridge, UK. 3The Clatterbridge Cancer Centre, Birkenhead, UK. 4Mount Vernon Cancer Centre, Northwood, UK. 5Bristol Myers Squibb, UXbridge, UK. 6Health Economics & Outcomes Research Ltd, Cardiff, UK.

Received: 9 November 2021 Accepted: 24 May 2022

Published online: 06 June 2022

References

1. European Network of Cancer Registries. Kidney cancer (KC) Factsheet. 2017. https://www.encr.eu/sites/default/files/factsheets/ENCR_Factsheet_Kidney_2017.pdf. Accessed 28 May 2021.
2. Cancer Research UK. Kidney cancer statistics. 2020. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/kidney-cancer#heading-Zero. Accessed 27 May 2020.
3. Kidney Care UK. Kidney Cancer. 2021. https://www.kidneycareuk.org/about-kidney-health/conditions/kidney-cancer/. Accessed 20 Jul 2021.
4. Cancer Research UK. Kidney cancer statistics; kidney cancer survival. 2021. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/kidney-cancer#heading-Zero. Accessed 10 Mar 2021.
5. Information Services Division (ISD) Scotland. Detect Cancer Early Staging Data: Year 7 (1 January 2017 to 31 December 2018). 2019. https://www.isdscotland.org/Health-Topics/Cancer/Publications/2019-08-13/2019-08-13-DetectCancerEarly-Report.pdf. Accessed 27 May 2020.
6. Queen’s University Belfast NICR. 2018 Cancer incidence, survival, mortality, and prevalence data. 2020. http://www.qub.ac.uk/research-centres/nicr/CancerInformation/official-statistics/. Accessed 27 May 2020.
7. National Cancer Registration and Analysis Service. Stage Breakdown by CCG. 2017. http://www.ncin.org.uk/publications/survival_by_stage. Accessed 27 May 2020.
8. Cancer Research UK. Kidney cancer diagnosis statistics. 2017. https://www.cancerresearchuk.org/health-professional/kidney-cancer-diagnosis-statistics#heading-Zero. Accessed 18 Feb 2021.
9. Choueiri TK, Motzer RJ. Systemic Therapy for Metastatic Renal-Cell Carcinoma. N Engl J Med. 2017;376(4):354–66.
10. Motzer RJ, Jonasch E, Agarwal N, et al. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(6):804–34.
11. Seebacher NA, Stacy AE, Porter GM, et al. Clinical development of targeted and immune-based anti-cancer therapies. J Exp Clin Cancer Res. 2019;38(1):156.
12. Guo L, Zhang H, Chen B, Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. J Cancer. 2017;8(3):410–6.
13. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.
14. Motzer RJ, Escudier B, George S, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020;126(18):4156–67.
15. Escudier B, Sharma P, McDermott DF, et al. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. Eur Urol. 2017;72(6):962–71.
16. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1803–13.
17. National Institute for Health and Care Excellence. Nivolumab for previously treated advanced renal cell carcinoma: TA417. 2017. https://www.nice.org.uk/guidance/ta417. Accessed 31 Oct 2018.
18. Kim HS, Lee S, Kim JH. Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records. J Korean Med Sci. 2018;33(34):e213.
19. Wagstaff J, Jones R, Hawkins R, et al. Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry. Ann Oncol. 2016;27(1):159–65.
20. Atkins MB, Tannir NM. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev. 2018;70:127–37.
21. NHS England. National Cancer Drugs Fund List. 2020. https://www.england.nhs.uk/wp-content/uploads/2017/04/national-cdf-list-ver1.165.pdf. Accessed 24 May 2021.
22. Kidney Cancer UK. Incidence of Kidney Cancer in the UK. 2020. https://www.kcuk.org.uk/kidneycancer/what-is-kidney-cancer/incidence-of-kidney-cancer-in-the-uk/. Accessed 1 Jun 2020.
23. Cancer Research UK. Kidney cancer: Types and grades. 2020. https://www.cancerresearchuk.org/about-cancer/kidney-cancer/stages-types-grades/types-grades. Accessed 1 June 2022.
24. National Institute for Health and Care Excellence. Single Technology Appraisal. Nivolumab with ipilimumab for untreated metastatic renal cell carcinoma [ID1182]. Committee Papers. 2018. Available at: https://www.nice.org.uk/guidance/ta581/documents/committee-papers. Accessed 1 Jan 2020.
25. National Institute for Health and Care Excellence. Sunitinib for the first-line treatment of advanced renal cell carcinoma. 2009. https://www.nice.org.uk/guidance/ta169. Accessed 10 Mar 2021.
26. National Institute for Health and Care Excellence. Pazopanib for the first-line treatment of advanced renal cell carcinoma. 2011. https://www.nice.org.uk/Guidance/TA215. Accessed 10 Mar 2021.
27. National Institute for Health and Care Excellence. Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment. 2015. https://www.nice.org.uk/Guidance/TA333. Accessed 10 Mar 2021.
28. National Institute for Health and Care Excellence. Cabozantinib for previously treated advanced renal cell carcinoma. 2017. https://www.nice.org.uk/Guidance/TA463. Accessed 10 Mar 2021.
29. National Institute for Health and Care Excellence. Everolimus for advanced renal cell carcinoma after previous treatment. 2017. https://www.nice.org.uk/Guidance/TA452. Accessed 10 Mar 2021.
30. National Institute for Health and Care Excellence. Lenvatinib with everolimus for previously treated advanced renal cell carcinoma. 2018. https://www.nice.org.uk/Guidance/TA498. Accessed 10 Mar 2021.
31. Verzoni E, Carenì G, Cortesi E, et al. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. J Immunother Cancer. 2019;7(1):99.
32. Verhaart SL, Abu-Ghanem Y, Mulder SF, et al. Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers. Clin Genitourin Cancer. 2020;19(3):274.e1-274.e16.
33. Vrdoljak E, Magi C, Gamulin M, et al. Real-world safety and efficacy of nivolumab for ≥ 2nd line treatment of metastatic renal cell carcinoma: A retrospective cohort study in Croatia, Hungary, and Malta. Neoplasma. 2021;68(1):208–15.
34. Salas-Vega S, Illeopoulou O, Mossialos E. Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines. JAMA Oncol. 2017;3(3):382–90.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.